Solid Tumors with Specific Mutations

IDH 1/2 mutant

BRCA Mutant

PTEN, PIK3CA

MGMT promoter hypermethylation positive

DNA repair; PI3K/AKT; RAS/RAF/MEK

inactivating ATM mutations, amplification of MYC; mutation of FBXW7, CCNE1 amplification, SWI/SNF member mutation

HER2-positive

10129: A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors

10222: Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH)-Mutant Solid Tumors

*10551: Phase I/Ib Study of Anti-CD47 Hu5F9-G4 (Magrolimab) in Combination with Olaparib in BRCA Mutant Patients with Metastatic or Recurrent Solid Tumors

▼10221: Phase I/I Biomarker-Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients with Advanced Solid Tumors (Limited: Phase 1 only; ETCTN-wide: Phase 2)

*▼10572: A Phase 1 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-Related Inhibitor M1774

10217: A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients with Advanced Solid Tumors (Expansion: germline or and somatic DDR aberrations; PIK3CA mutant; PTEN loss)

▼10329: Phase I Sequential Trial of Agents Against DNA Repair (STAR) (Dose escalation: enriched for DDR aberrations; Expansion: Cohort A: BRCA1/2; Cohort B: DDR aberrations; Limited: Phase 1 only; ETCTN-wide: Phase 2)

10371: A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients with Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response

*10528: Phase 1 study of the POLq inhibitor Novobiocin in BRCA-mutant and other DNA damage repair-deficient solid tumors

*10527: A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774

▼10346: Pilot Study of DS-8201a Pharmacodynamics in Patients with HER2-Expressing Advanced Solid Tumors

10355: A Phase I Study of DS-8201a in Combination with Olaparib in HER2-Expressing Malignancies

10358: Phase 1/1B Study of DS-8201a in Combination with ATR Inhibition (AZD6738) in Advanced Solid Tumors with HER2 Expression (DASH Trial)

10495: Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination with Neratinib in Solid Tumors with HER2 Alterations

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: December 8, 2022